spain

Biotechnology strengthens its position in Spain

The sales in the sector of the so-called Bioeconomy, has grown from 2.98% GDP (PIB in Spanish) in 2008 to 7.8% in 2012, according to the Asebio report, recently published. Companies stating that biotechnology is their main or only activity –among which Bionaturis is- registered an increase of 10.78% in their sales (8,800 million Euros) and 5% of rise in net employment during 2012, surpassing its own expectations for a year that it has been forecasted very complicated for Spanish economy.

According to Bionaturis’ CEO, Victor Infante, who attended the ASEBIO gala , “apart from the figures that prove that the biotech sector has performed better than others at this time of recession, I´d like to stand out some words heard today such as the need of innovation in all fields, including the relationship with public administrations, patients associations, regulatory authorities, partners at the value chain, with the main goal of seeking sustainability of the health system as a whole; or those promoting to seek talent wherever it is”.

More internationalization

85% of Asebio’s members conducted some international activity in 2013, as Bionaturis did. For the first time since this survey has been done, the associated companies consider LATAM as one of their priority market in their international strategy, specially Mexico (96.67%) and Colombia (95.83%). The European Union (93.24%), Switzerland (90.48%) and USA (88.41%) keep on having a leadership position for international operations.

During 2013, 57 companies and Spanish Organizations from the biotechnological sector (+39% regarding to 2012) signed a total of 108 international business partnerships (+42%).

August 1st, 2014|Blog english|0 Comments|

2014, Year of Biotechnology in Spain

The biotech sector has one more reason to begin the new year with energy and eagerness, considering that 2014 has been quoted by the Spanish Government as the Year of Biotechnology. The Spanish Federation of Biotechnologists, along with the Spanish Society of Biotechnology (SEbiot), the Spanish Society of Microbiology (SEM), and the Spanish Association of Bio Enterprises (Asebio), have been the boosters of this initiative, which involves an important support for the industry and its professionals. In their words, the goal of this year is “not only continue encouraging the Spanish Biotech in all its sides, both research and industrial, but also improving its teaching and social concern. It’s about summing up, putting Biotech in the centre of society”.

Among the main goals of this commemoration, we have to highlight fostering Biotech research in Spain, the improvement of its teaching and dissemination, and the rise of the cooperation between the public and private sector in this field.

According to statistics from the Asebio annual report, the number of biotech companies grew more than 70% in 2011. Cataluña, Madrid and Adalucía –where Bionaturis is located- are the regions gathering more companies in this sector. The OECD ranked Spain in 2012 as the second country of the European Union with a bigger number of biotech companies.

Bionaturis congratulates the initiative and will support this commemoration, forecasting a great year for the global sector in which fostering R+D will have a key role.

Talents back home

Bionaturis, an international reference company in developing biological vaccines, contributes to recover young talents that had to emigrate out of our borders to start or continue their professional careers.

According to one of the few studies that exist about that, made by the Spanish National Institute of Statistics (INE), between 2000 and 2009, 21% of the Spanish PhDs left Spain to work in another country. The grants cost cuttings and the adjustments of employment in research centres and universities have forced the experts to go out of the country. The overall budget in R&D has decreased more than 40% since 2009.

In view of the situation, Bionaturis bets on “Spanish returnees”. Some of them are part of the young and qualified staff of this company based on innovation and research. For example, Begoña Roibas, now Project Manager at Bionaturis, was working in the National University of Seoul during two years before coming back to Spain. Our Chief Scientific Officer (CSO), Juan Jose Infante, worked also during four years in Washington University (USA). They gained experience abroad and now they´re contributing to the company growth.

If you want to read the full report about our Project Manager, Begoña Roibas, in El Mundo, please click here

Business Angels getting closer to Spanish newborn companies

New Entrepreneurial Act -passed by the Spanish Congress last July- supports the figure of the ‘Business Angels’, private investors that, in group or individually, invest on the growth of a company which is usually located around them. In recent years, this way of funding has meant an important incentive for Small and Medium-Sized Enterprises (SMEs) and entrepreneurs against the problems found nowadays in the traditional systems of bank funding.

Thanks to this new act (still to be approved by the Senate) ‘Business Angels’ will have twenty per cent tax reduction from Income Tax with a maximum discount of 50,000 Euros per year.

The extension of limited fees for self-employed and supporting measures to stimulate bank loans to companies are other measures included in the new act.

If you want to know the act in detail, please click here

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR